| Malignant neoplasm of prostate
Posluma vs Trelstar
Side-by-side clinical, coverage, and cost comparison for malignant neoplasm of prostate.Deep comparison between: Posluma vs Trelstar with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTrelstar has a higher rate of injection site reactions vs Posluma based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Trelstar but not Posluma, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Posluma
Trelstar
At A Glance
IV injection
PSMA-targeted radiodiagnostic
IM injection
Every 4-24 weeks
GnRH agonist
Indications
- Malignant neoplasm of prostate
- Malignant neoplasm of prostate
Dosing
Malignant neoplasm of prostate 296 MBq (8 mCi) as a single intravenous bolus injection; begin imaging approximately 60 minutes after administration from mid-thigh to base of skull.
Malignant neoplasm of prostate 3.75 mg by single IM injection every 4 weeks, 11.25 mg every 12 weeks, or 22.5 mg every 24 weeks; strengths are not additive and must be selected based on the desired dosing schedule.
Contraindications
—
- Known hypersensitivity to triptorelin or any other component of the product, or other GnRH agonists or GnRH
Adverse Reactions
Most common (>=0.4%) Diarrhea, blood pressure increase, injection site pain
Most common (>=1%) Hot flush, skeletal pain, headache, impotence/erectile dysfunction, hypertension, injection site pain, edema, dysuria, urinary tract infection, insomnia
Serious Tumor flare, hypersensitivity reactions, metabolic syndrome, cardiovascular disease, convulsions, severe cutaneous adverse reactions, QT/QTc prolongation, spinal cord compression
Postmarketing Pituitary apoplexy, cerebrovascular accident, myocardial infarction, pulmonary emboli, thromboembolic events, convulsions, non-alcoholic fatty liver disease, interstitial lung disease, SJS/TEN, DRESS, AGEP, erythema multiforme
Pharmacology
PSMA-targeted radiodiagnostic agent; flotufolastat F 18 binds to PSMA (IC50 = 4.4 nM) on prostate cancer cells, which overexpress PSMA, and is internalized; fluorine-18 emits positrons detectable by PET.
Triptorelin is a synthetic decapeptide GnRH agonist; chronic continuous administration suppresses LH and FSH secretion and markedly reduces testicular steroidogenesis, achieving medical castration levels of testosterone in men with advanced prostate cancer.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
No coverage data available for Posluma.
Trelstar
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
No coverage data available for Posluma.
Trelstar
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (1/8) · Qty limit (1/8)
Humana
No coverage data available for Posluma.
Trelstar
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Posluma.
Cost estimate not availableAssistance Fund: Prostate Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
PoslumaView full Posluma profile
TrelstarView full Trelstar profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.